


Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFN γ pathways

Xue Bai, David E. Fisher and Keith T. Flaherty

<https://doi.org/10.1038/s41571-019-0204-6>



Supplementary Fig. 1 | Signalling molecules downstream of MITF. Colour code: green: pro-proliferation; pink: pro-invasiveness; brown: mixed function; orange: resistance to targeted therapy/immunotherapy; yellow: anti-resistance; blue: pro-immune response; grey: not related to above-mentioned functions. Font colour: role of the molecule as a whole. Shadow colour: particular role of the molecule under certain specific setting. Numbers refer to references in supplementary data.

References

1. McGill GG, Haq R, Nishimura EK, et al. c-Met expression is regulated by Mitf in the melanocyte lineage. *J Biol Chem.* 2006 Apr 14;281(15):10365-73.
2. Carreira S, Goodall J, Aksan I, et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. *Nature.* 2005 Feb 17;433(7027):764-9.
3. Hsiao JJ, Fisher DE. The roles of microphthalmia-associated transcription factor and pigmentation in melanoma. *Arch Biochem Biophys.* 2014 Dec 1;563:28-34. doi: 10.1016/j.abb.2014.07.019.


4. Loercher AE, Tank EM, Delston RB, et al. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. *J Cell Biol.* 2005 Jan 3;168(1):35-40.
5. Thurber AE, Douglas G, Sturm EC, et al. Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway. *Oncogene.* 2011 Jul 7;30(27):3036-48. doi: 10.1038/onc.2011.33.
6. Fane ME, Chhabra Y, Hollingsworth DEJ, et al. NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF. *EBioMedicine.* 2017 Feb;16:63-75. doi: 10.1016/j.ebiom.2017.01.013.
7. Leibowitz-Amit R, Sidi Y, Avni D. Aberrations in the micro-RNA biogenesis machinery and the emerging roles of micro-RNAs in the pathogenesis of cutaneous malignant melanoma. *Pigment Cell Melanoma Res.* 2012 Nov;25(6):740-57. doi: 10.1111/pcmr.12018.
8. Saladi SV, Wong PG, Trivedi AR, et al. BRG1 promotes survival of UV-irradiated melanoma cells by cooperating with MITF to activate the melanoma inhibitor of apoptosis gene. *Pigment Cell Melanoma Res.* 2013 May;26(3):377-91. doi: 10.1111/pcmr.12088.
9. Falletta P, Sanchez-Del-Campo L, Chauhan J, et al. Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma. *Genes Dev.* 2017 Jan 1;31(1):18-33. doi: 10.1101/gad.290940.116.
10. Ji Z, Erin Chen Y1, Kumar R, et al. MITF Modulates Therapeutic Resistance through EGFR Signaling. *J Invest Dermatol.* 2015 Jul;135(7):1863-1872. doi: 10.1038/jid.2015.105.
11. Sun C, Wang L, Huang S, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. *Nature.* 2014 Apr 3;508(7494):118-22. doi: 10.1038/nature13121.
12. Kim H, Frederick DT, Levesque MP, et al. Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Dereglulation. *Cell Rep.* 2015 Jun 9;11(9):1458-73. doi: 10.1016/j.celrep.2015.04.049.
13. Haq R, Shoag J, Andreu-Perez P, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1 α and MITF. *Cancer Cell.* 2013 Mar 18;23(3):302-15. doi: 10.1016/j.ccr.2013.02.003.
14. Abildgaard C, Guldborg P. Molecular drivers of cellular metabolic reprogramming in melanoma. *Trends Mol Med.* 2015 Mar;21(3):164-71. doi: 10.1016/j.molmed.2014.12.007.
15. Gupta PB, Kuperwasser C, Brunet JP, et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. *Nat Genet.* 2005 Oct;37(10):1047-54.
16. Shirley SH, Greene VR, Duncan LM, et al. Slug expression during melanoma progression. *Am J Pathol.* 2012 Jun;180(6):2479-89. doi: 10.1016/j.ajpath.2012.02.014.

17. Dissanayake SK, Wade M, Johnson CE, et al. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. *J Biol Chem*. 2007 Jun 8;282(23):17259-71.
18. Hao L, Ha JR, Kuzel P, et al. Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail. *Br J Dermatol*. 2012 Jun;166(6):1184-97. doi: 10.1111/j.1365-2133.2012.10824.x.
19. Fenouille N, Tichet M, Dufies M, et al. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. *PLoS One*. 2012;7(7):e40378. doi: 10.1371/journal.pone.0040378.
20. O'Connell MP, Marchbank K, Webster MR, et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. *Cancer Discov*. 2013 Dec;3(12):1378-93. doi: 10.1158/2159-8290.CD-13-0005.
21. Slominski A, Kim TK, Brożyna AA, et al. The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1 α expression and HIF-dependent attendant pathways. *Arch Biochem Biophys*. 2014 Dec 1;563:79-93. doi: 10.1016/j.abb.2014.06.030.
22. Yajima I, Kumasaka MY, Thang ND, et al. Molecular Network Associated with MITF in Skin Melanoma Development and Progression. *J Skin Cancer*. 2011;2011:730170. doi: 10.1155/2011/730170.
23. Liu F, Fu Y, Meyskens FL Jr. Mitf regulates cellular response to reactive oxygen species through transcriptional regulation of APE-1/Ref-1. *J Invest Dermatol*. 2009 Feb;129(2):422-31. doi: 10.1038/jid.2008.255.
24. Hartman ML, Czyz M. Pro-survival role of MITF in melanoma. *J Invest Dermatol*. 2015 Feb;135(2):352-358. doi: 10.1038/jid.2014.319.
25. Trisciuglio D, Gabellini C, Desideri M, et al. Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells. *Cell Death Differ*. 2011 Jun;18(6):1024-35. doi: 10.1038/cdd.2010.175.
26. Webster DE, Barajas B, Bussat RT, et al. Enhancer-targeted genome editing selectively blocks innate resistance to onco-kinase inhibition. *Genome Res*. 2014 May;24(5):751-60. doi: 10.1101/gr.166231.113.
27. Buscà R, Berra E, Gaggioli C, et al. Hypoxia-inducible factor 1 α is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. *J Cell Biol*. 2005 Jul 4;170(1):49-59.
28. Regad T. Molecular and cellular pathogenesis of melanoma initiation and progression. *Cell Mol Life Sci*. 2013 Nov;70(21):4055-65. doi: 10.1007/s00018-013-1324-2.
29. Cheli Y, Giuliano S, Botton T, et al. Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. *Oncogene*. 2011 May 19;30(20):2307-18. doi: 10.1038/onc.2010.598.

30. Carreira S, Goodall J, Denat L, et al. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. *Genes Dev.* 2006 Dec 15;20(24):3426-39.
31. Lamouille S, Xu J2, Erynck R1. Molecular mechanisms of epithelial-mesenchymal transition. *Nat Rev Mol Cell Biol.* 2014 Mar;15(3):178-96. doi: 10.1038/nrm3758.
32. Rose AA, Annis MG, Frederick DT, et al. MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB. *Clin Cancer Res.* 2016 Dec 15;22(24):6088-6098.
33. Smith MP, Rowling EJ, Miskolczi Z, et al. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. *EMBO Mol Med.* 2017 Aug;9(8):1011-1029. doi: 10.15252/emmm.201607156.
34. Haq R, Yokoyama S, Hawryluk EB, et al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. *Proc Natl Acad Sci U S A.* 2013 Mar 12;110(11):4321-6. doi: 10.1073/pnas.1205575110.
35. Alver TN, Lavelle TJ, Longva AS, et al. MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma. *Oncotarget.* 2016 Aug 23;7(34):55128-55140. doi: 10.18632/oncotarget.10422.
36. Riesenberger S, Groetchen A, Siddaway R, et al. MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. *Nat Commun.* 2015 Nov 4;6:8755. doi: 10.1038/ncomms9755.
37. Felicetti F, Errico MC, Bottero L, et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. *Cancer Res.* 2008 Apr 15;68(8):2745-54. doi: 10.1158/0008-5472.CAN-07-2538.
38. Lunavat TR, Cheng L, Einarsdottir BO, et al. BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells. *Proc Natl Acad Sci U S A.* 2017 Jul 18;114(29):E5930-E5939. doi: 10.1073/pnas.1705206114.
39. Levy C, Khaled M, Iliopoulos D, et al. Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. *Mol Cell.* 2010 Dec 10;40(5):841-9. doi: 10.1016/j.molcel.2010.11.020.
40. De Luca T, Pelosi A, Triscioglio D, et al. miR-211 and MITF modulation by Bcl-2 protein in melanoma cells. *Mol Carcinog.* 2016 Dec;55(12):2304-2312. doi: 10.1002/mc.22437.
41. Dai X, Rao C, Li H, et al. Regulation of pigmentation by microRNAs: MITF-dependent microRNA-211 targets TGF- β receptor 2. *Pigment Cell Melanoma Res.* 2015 Mar;28(2):217-22. doi: 10.1111/pcmr.12334.
42. Dar AA, Majid S, Bezrookove V, et al. BPTF transduces MITF-driven prosurvival signals in melanoma cells. *Proc Natl Acad Sci U S A.* 2016 May 31;113(22):6254-8. doi: 10.1073/pnas.1606027113.

43. McGill GG, Horstmann M, Widlund HR, et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. *Cell*. 2002 Jun 14;109(6):707-18.
44. Du J, Widlund HR, Horstmann MA, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. *Cancer Cell*. 2004 Dec;6(6):565-76.
45. Wellbrock C, Rana S, Paterson H, et al. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. *PLoS One*. 2008 Jul 16;3(7):e2734. doi: 10.1371/journal.pone.0002734.
46. Kaur A, Webster MR, Marchbank K, et al. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. *Nature*. 2016 Apr 14;532(7598):250-4. doi: 10.1038/nature17392.
47. Fernández-Barral A, Orgaz JL, Baquero P, et al. Regulatory and functional connection of microphthalmia-associated transcription factor and anti-metastatic pigment epithelium derived factor in melanoma. *Neoplasia*. 2014 Jun;16(6):529-42. doi: 10.1016/j.neo.2014.06.001.
48. Ohanna M, Bonet C, Bille K, et al. SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells. *Oncotarget*. 2014 Apr 30;5(8):2085-95.
49. Dynek JN, Chan SM, Liu J, et al. Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. *Cancer Res*. 2008 May 1;68(9):3124-32. doi: 10.1158/0008-5472.CAN-07-6622.
50. Seberg HE, Van Otterloo E, Cornell RA. Beyond MITF: Multiple transcription factors directly regulate the cellular phenotype in melanocytes and melanoma. *Pigment Cell Melanoma Res*. 2017 Sep;30(5):454-466. doi: 10.1111/pcmr.12611.
51. Khaled M, Levy C, Fisher DE. Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit. *Genes Dev*. 2010 Oct 15;24(20):2276-81. doi: 10.1101/gad.1937710.
52. Du J, Fisher DE. Identification of Aim-1 as the underwhite mouse mutant and its transcriptional regulation by MITF. *J Biol Chem*. 2002 Jan 4;277(1):402-6.
53. Liu JJ, Fisher DE. Lighting a path to pigmentation: mechanisms of MITF induction by UV. *Pigment Cell Melanoma Res*. 2010 Dec;23(6):741-5. doi: 10.1111/j.1755-148X.2010.00775.x.
54. Tomihari M, Chung JS, Akiyoshi H, et al. DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells. *Cancer Res*. 2010 Jul 15;70(14):5778-87. doi: 10.1158/0008-5472.CAN-09-2538.
55. Buckanovich RJ, Facciabene A, Kim S, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. *Nat Med*. 2008 Jan;14(1):28-36.
56. Giuliano S, Cheli Y, Ohanna M, et al. Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence

- program in melanomas. *Cancer Res.* 2010 May 1;70(9):3813-22. doi: 10.1158/0008-5472.CAN-09-2913.
57. Strub T, Giuliano S, Ye T, et al. Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. *Oncogene.* 2011 May 19;30(20):2319-32. doi: 10.1038/onc.2010.612.
58. Levy C, Khaled M, Robinson KC, et al. Lineage-specific transcriptional regulation of DICER by MITF in melanocytes. *Cell.* 2010 Jun 11;141(6):994-1005. doi: 10.1016/j.cell.2010.05.004.
59. Beuret L, Ohanna M, Strub T, et al. BRCA1 is a new MITF target gene. *Pigment Cell Melanoma Res.* 2011 Aug;24(4):725-7. doi: 10.1111/j.1755-148X.2011.00862.x.
60. Mascarenhas JB, Littlejohn EL, Wolsky RJ, et al. PAX3 and SOX10 activate MET receptor expression in melanoma. *Pigment Cell Melanoma Res.* 2010 Apr;23(2):225-37. doi: 10.1111/j.1755-148X.2010.00667.x.



Supplementary Fig. 2 | MITF regulatory network. Colour code: green: pro-MITF; pink: anti-MITF; brown: mixed function. Font colour: role (pro-MITF versus anti-MITF versus mixed function) of the molecule as a whole. Shadow colour: particular role of the molecule under certain specific setting. Numbers refer to references in supplementary data.

References

1. Lo JA, Fisher DE. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. *Science*. 2014 Nov 21;346(6212):945-9. doi: 10.1126/science.1253735.
2. Sestáková B, Ondrusová L, Vachtenheim J. Cell cycle inhibitor p21/WAF1/CIP1 as a cofactor of MITF expression in melanoma cells. *Pigment Cell Melanoma Res*. 2010 Apr;23(2):238-51. doi: 10.1111/j.1755-148X.2010.00670.x.
3. Hartman ML, Czyz M. Pro-survival role of MITF in melanoma. *J Invest Dermatol*. 2015 Feb;135(2):352-358. doi: 10.1038/jid.2014.319.
4. Ramsdale R, Jorissen RN, Li FZ, et al. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. *Sci Signal*. 2015 Aug 18;8(390):ra82. doi: 10.1126/scisignal.aab1111.
5. Mujahid N, Liang Y, Murakami R, et al. A UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin. *Cell Rep*. 2017 Jun 13;19(11):2177-2184. doi: 10.1016/j.celrep.2017.05.042.

6. Son J, Kim M, Jou I, et al. IFN- γ inhibits basal and α -MSH-induced melanogenesis. *Pigment Cell Melanoma Res.* 2014 Mar;27(2):201-8. doi: 10.1111/pcmr.12190.
7. Javelaud D, Alexaki VI, Pierrat MJ, et al. GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells. *Pigment Cell Melanoma Res.* 2011 Oct;24(5):932-43. doi: 10.1111/j.1755-148X.2011.00893.x.
8. Wellbrock C, Arozarena I. Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. *Pigment Cell Melanoma Res.* 2015 Jul;28(4):390-406. doi: 10.1111/pcmr.12370.
9. Perotti V, Baldassari P, Molla A, et al. NFATc2 is an intrinsic regulator of melanoma dedifferentiation. *Oncogene.* 2016 Jun 2;35(22):2862-72. doi: 10.1038/onc.2015.355.
10. Wellbrock C, Rana S, Paterson H, et al. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. *PLoS One.* 2008 Jul 16;3(7):e2734. doi: 10.1371/journal.pone.0002734.
11. Regad T. Molecular and cellular pathogenesis of melanoma initiation and progression. *Cell Mol Life Sci.* 2013 Nov;70(21):4055-65. doi: 10.1007/s00018-013-1324-2.
12. Shah M, Bhoumik A, Goel V, et al. A role for ATF2 in regulating MITF and melanoma development. *PLoS Genet.* 2010 Dec 23;6(12):e1001258. doi: 10.1371/journal.pgen.1001258.
13. Sensi M, Catani M, Castellano G, et al. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. *J Invest Dermatol.* 2011 Dec;131(12):2448-57. doi: 10.1038/jid.2011.218.
14. Zhu S, Wurdak H, Wang Y, et al. A genomic screen identifies TYRO3 as a MITF regulator in melanoma. *Proc Natl Acad Sci U S A.* 2009 Oct 6;106(40):17025-30. doi: 10.1073/pnas.0909292106.
15. Katoh M, Katoh M. Transcriptional mechanisms of WNT5A based on NF- κ B, Hedgehog, TGF β , and Notch signaling cascades. *Int J Mol Med.* 2009 Jun;23(6):763-9.
16. Eichhoff OM, Weeraratna A, Zipser MC, et al. Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. *Pigment Cell Melanoma Res.* 2011 Aug;24(4):631-42. doi: 10.1111/j.1755-148X.2011.00871.x.
17. Topol L, Jiang X, Choi H, et al. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. *J Cell Biol.* 2003 Sep 1;162(5):899-908.
18. Huber WE, Price ER, Widlund HR, et al. A tissue-restricted cAMP transcriptional response: SOX10 modulates alpha-melanocyte-stimulating hormone-triggered expression of microphthalmia-associated transcription factor in melanocytes. *J Biol Chem.* 2003 Nov 14;278(46):45224-30. Epub 2003 Aug 27.

19. Takeda K, Yasumoto K, Takada R, et al. Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a. *J Biol Chem*. 2000 May 12;275(19):14013-6.
20. Hartman ML, Czyz M. MITF in melanoma: mechanisms behind its expression and activity. *Cell Mol Life Sci*. 2015 Apr;72(7):1249-60. doi: 10.1007/s00018-014-1791-0.
21. Gajos-Michniewicz A, Czyz M2. Modulation of WNT/ β -catenin pathway in melanoma by biologically active components derived from plants. *Fitoterapia*. 2016 Mar;109:283-92. doi: 10.1016/j.fitote.2016.02.002.
22. Schepsky A, Bruser K, Gunnarsson GJ, et al. The microphthalmia-associated transcription factor Mitf interacts with beta-catenin to determine target gene expression. *Mol Cell Biol*. 2006 Dec;26(23):8914-27.
23. Regad T. Molecular and cellular pathogenesis of melanoma initiation and progression. *Cell Mol Life Sci*. 2013 Nov;70(21):4055-65. doi: 10.1007/s00018-013-1324-2.
24. Konieczkowski DJ, Johannessen CM, Abudayyeh O, et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. *Cancer Discov*. 2014 Jul;4(7):816-27. doi: 10.1158/2159-8290.CD-13-0424.
25. Paluncic J, Kovacevic Z, Jansson PJ, et al. Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling. *Biochim Biophys Acta*. 2016 Apr;1863(4):770-84. doi: 10.1016/j.bbamcr.2016.01.025.
26. Damsky WE, Curley DP, Santhanakrishnan M, et al. β -catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. *Cancer Cell*. 2011 Dec 13;20(6):741-54. doi: 10.1016/j.ccr.2011.10.030.
27. Widlund HR, Horstmann MA, Price ER, et al. Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. *J Cell Biol*. 2002 Sep 16;158(6):1079-87.
28. Falletta P, Sanchez-Del-Campo L, Chauhan J, et al. Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma. *Genes Dev*. 2017 Jan 1;31(1):18-33. doi: 10.1101/gad.290940.116.
29. Smith MP, Sanchez-Laorden B, O'Brien K, et al. The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNF α . *Cancer Discov*. 2014 Oct;4(10):1214-1229. doi: 10.1158/2159-8290.CD-13-1007.
30. Choi J, Xu M, Makowski MM, et al. A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF. *Nat Genet*. 2017 Sep;49(9):1326-1335. doi: 10.1038/ng.3927.
31. Smith MP, Ferguson J, Arozarena I, et al. Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. *J Natl Cancer Inst*. 2013 Jan 2;105(1):33-46. doi: 10.1093/jnci/djs471.

32. Medic S, Ziman M. PAX3 across the spectrum: from melanoblast to melanoma. *Crit Rev Biochem Mol Biol.* 2009 Jun;44(2-3):85-97. doi: 10.1080/10409230902755056.
33. Basile KJ, Abel EV, Aplin AE. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. *Oncogene.* 2012 May 10;31(19):2471-9. doi: 10.1038/onc.2011.424.
34. Wan P, Hu Y, He L. Regulation of melanocyte pivotal transcription factor MITF by some other transcription factors. *Mol Cell Biochem.* 2011 Aug;354(1-2):241-6. doi: 10.1007/s11010-011-0823-4.
35. Loeken MR. How TGF-beta and PAX3 regulate suntanning. *Pigment Cell Melanoma Res.* 2009 Apr;22(2):146-7. doi: 10.1111/j.1755-148X.2009.00541.x.
36. Yang G, Li Y, Nishimura EK, et al. Inhibition of PAX3 by TGF-beta modulates melanocyte viability. *Mol Cell.* 2008 Nov 21;32(4):554-63. doi: 10.1016/j.molcel.2008.11.002.
37. Kubic JD, Little EC, Kaiser RS, et al. FOXD3 Promotes PAX3 Expression in Melanoma Cells. *J Cell Biochem.* 2016 Feb;117(2):533-41. doi: 10.1002/jcb.25306.
38. Dong L, Li Y, Cao J, et al. FGF2 regulates melanocytes viability through the STAT3-transactivated PAX3 transcription. *Cell Death Differ.* 2012 Apr;19(4):616-22. doi: 10.1038/cdd.2011.132.
39. Pawlus MR, Wang L, Hu CJ. STAT3 and HIF1 α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells. *Oncogene.* 2014 Mar 27;33(13):1670-9. doi: 10.1038/onc.2013.115.
40. Feige E, Yokoyama S, Levy C, et al. Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF. *Proc Natl Acad Sci U S A.* 2011 Oct 25;108(43):E924-33. doi: 10.1073/pnas.1106351108.
41. Thingnes J, Lavelle TJ, Gjuvslund AB, et al. Towards a quantitative understanding of the MITF-PIAS3-STAT3 connection. *BMC Syst Biol.* 2012 Feb 8;6:11. doi: 10.1186/1752-0509-6-11.
42. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. *Nat Rev Cancer.* 2012 Apr 5;12(5):349-61. doi: 10.1038/nrc3218.
43. Richard G, Dalle S, Monet MA, et al. ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors. *EMBO Mol Med.* 2016 Oct 4;8(10):1143-1161. doi: 10.15252/emmm.201505971.
44. Ji Z, Erin Chen Y1, Kumar R, et al. MITF Modulates Therapeutic Resistance through EGFR Signaling. *J Invest Dermatol.* 2015 Jul;135(7):1863-1872. doi: 10.1038/jid.2015.105.
45. Jané-Valbuena J, Widlund HR, Perner S, et al. An oncogenic role for ETV1 in melanoma. *Cancer Res.* 2010 Mar 1;70(5):2075-84. doi: 10.1158/0008-5472.CAN-09-3092.
46. Cook AL, Smith AG, Smit DJ, et al. Co-expression of SOX9 and SOX10 during melanocytic differentiation in vitro. *Exp Cell Res.* 2005 Aug 1;308(1):222-35.

47. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. *Nat Rev Mol Cell Biol.* 2014 Mar;15(3):178-96. doi: 10.1038/nrm3758.
48. Vandamme N, Berx G. Melanoma cells revive an embryonic transcriptional network to dictate phenotypic heterogeneity. *Front Oncol.* 2014 Dec 9;4:352. doi: 10.3389/fonc.2014.00352.
49. Smith MP, Brunton H, Rowling EJ, et al. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. *Cancer Cell.* 2016 Mar 14;29(3):270-84. doi: 10.1016/j.ccell.2016.02.003.
50. Boyle GM, Woods SL, Bonazzi VF, et al. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. *Pigment Cell Melanoma Res.* 2011 Jun;24(3):525-37. doi: 10.1111/j.1755-148X.2011.00849.x.
51. Liu F, Cao J, Wu J, et al. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. *J Invest Dermatol.* 2013 Aug;133(8):2041-9. doi: 10.1038/jid.2013.32.
52. Goodall J, Martinozzi S, Dexter TJ, et al. Brn-2 expression controls melanoma proliferation and is directly regulated by beta-catenin. *Mol Cell Biol.* 2004 Apr;24(7):2915-22.
53. O'Connell MP, Marchbank K, Webster MR, et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. *Cancer Discov.* 2013 Dec;3(12):1378-93. doi: 10.1158/2159-8290.CD-13-0005.
54. Genovese G, Ghosh P, Li H, et al. The tumor suppressor HINT1 regulates MITF and β -catenin transcriptional activity in melanoma cells. *Cell Cycle.* 2012 Jun 1;11(11):2206-15. doi: 10.4161/cc.20765.
55. Cheli Y, Giuliano S, Fenouille N, et al. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. *Oncogene.* 2012 May 10;31(19):2461-70. doi: 10.1038/onc.2011.425.
56. Denecker G, Vandamme N, Akay O, et al. Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. *Cell Death Differ.* 2014 Aug;21(8):1250-61. doi: 10.1038/cdd.2014.44.
57. Caramel J, Papadogeorgakis E, Hill L, et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. *Cancer Cell.* 2013 Oct 14;24(4):466-80. doi: 10.1016/j.ccr.2013.08.018.
58. van den Hurk K, Niessen HE, Veeck J, et al. Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune. *Biochim Biophys Acta.* 2012 Aug;1826(1):89-102. doi: 10.1016/j.bbcan.2012.03.011.
59. Vachtenheim J, Ondrusová L, Borovanský J. SWI/SNF chromatin remodeling complex is critical for the expression of microphthalmia-associated transcription factor in melanoma cells. *Biochem Biophys Res Commun.* 2010 Feb 12;392(3):454-9. doi: 10.1016/j.bbrc.2010.01.048.

60. Ohanna M, Cheli Y, Bonet C, et al. Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype. *Oncotarget*. 2013 Dec;4(12):2212-24.
61. Vachtenheim J, Ondrušová L. Microphthalmia-associated transcription factor expression levels in melanoma cells contribute to cell invasion and proliferation. *Exp Dermatol*. 2015 Jul;24(7):481-4. doi: 10.1111/exd.12724.
62. Kubic JD, Mascarenhas JB, Iizuka T, et al. GSK-3 promotes cell survival, growth, and PAX3 levels in human melanoma cells. *Mol Cancer Res*. 2012 Aug;10(8):1065-76. doi: 10.1158/1541-7786.MCR-11-0387.
63. Berlin I, Denat L, Steunou AL, et al. Phosphorylation of BRN2 modulates its interaction with the Pax3 promoter to control melanocyte migration and proliferation. *Mol Cell Biol*. 2012 Apr;32(7):1237-47. doi: 10.1128/MCB.06257-11.
64. Hathaway-Schrader JD, Doonan BP, Hossain A, et al. Autophagy-dependent crosstalk between GILT and PAX-3 influences radiation sensitivity of human melanoma cells. *J Cell Biochem*. 2018 Feb;119(2):2212-2221. doi: 10.1002/jcb.26383.
65. Meierjohann S. Crosstalk signaling in targeted melanoma therapy. *Cancer Metastasis Rev*. 2017 Mar;36(1):23-33. doi: 10.1007/s10555-017-9659-z.
66. Sinnberg T, Makino E, Krueger MA, et al. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib. *EBioMedicine*. 2016 Jun;8:132-149. doi: 10.1016/j.ebiom.2016.04.037.
67. Stanisz H, Saul S, Müller CS, et al. Inverse regulation of melanoma growth and migration by Orai1/STIM2-dependent calcium entry. *Pigment Cell Melanoma Res*. 2014 May;27(3):442-53. doi: 10.1111/pcmr.12222.
68. Bonvin E, Falletta P, Shaw H, et al. A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma. *Mol Cell Biol*. 2012 Nov;32(22):4674-83. doi: 10.1128/MCB.01067-12.
69. Cao J, Dai X, Wan L, et al. The E3 ligase APC/C(Cdh1) promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth. *Sci Signal*. 2015 Sep 1;8(392):ra87. doi: 10.1126/scisignal.aab1995.
70. Lee HJ, Zhuang G, Cao Y, et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. *Cancer Cell*. 2014 Aug 11;26(2):207-21. doi: 10.1016/j.ccr.2014.05.019.
71. Sun C, Wang L, Huang S, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. *Nature*. 2014 Apr 3;508(7494):118-22. doi: 10.1038/nature13121.
72. Dissanayake SK, Olkhanud PB, O'Connell MP, et al. Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. *Cancer Res*. 2008 Dec 15;68(24):10205-14. doi: 10.1158/0008-5472.CAN-08-2149.

73. Kordaß T, Weber CE, Oswald M, et al. SOX5 is involved in balanced MITF regulation in human melanoma cells. *BMC Med Genomics*. 2016 Feb 29;9:10. doi: 10.1186/s12920-016-0170-0.
74. Seberg HE, Van Otterloo E, Cornell RA. Beyond MITF: Multiple transcription factors directly regulate the cellular phenotype in melanocytes and melanoma. *Pigment Cell Melanoma Res*. 2017 Sep;30(5):454-466. doi: 10.1111/pcmr.12611.
75. Cimadamore F, Shah M, Amador-Arjona A, et al. SOX2 modulates levels of MITF in normal human melanocytes, and melanoma lines in vitro. *Pigment Cell Melanoma Res*. 2012 Jul;25(4):533-6. doi: 10.1111/j.1755-148X.2012.01012.x.
76. Prasad CP, Mohapatra P, Andersson T. Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer? *Cancers (Basel)*. 2015 Sep 17;7(3):1900-24. doi: 10.3390/cancers7030868.
77. Manderfield LJ, Engleka KA, Aghajanian H, et al. Pax3 and hippo signaling coordinate melanocyte gene expression in neural crest. *Cell Rep*. 2014 Dec 11;9(5):1885-95. doi: 10.1016/j.celrep.2014.10.061.
78. D'Mello SA, Finlay GJ, Baguley BC, et al. Signaling Pathways in Melanogenesis. *Int J Mol Sci*. 2016 Jul 15;17(7). pii: E1144. doi: 10.3390/ijms17071144.
79. Mallarino R, Henegar C, Mirasierra M, et al. Developmental mechanisms of stripe patterns in rodents. *Nature*. 2016 Nov 24;539(7630):518-523. doi: 10.1038/nature20109.
80. Xia M, Chen K, Yao X, et al. Mediator MED23 Links Pigmentation and DNA Repair through the Transcription Factor MITF. *Cell Rep*. 2017 Aug 22;20(8):1794-1804. doi: 10.1016/j.celrep.2017.07.056.
81. Goodall J, Carreira S, Denat L, et al. Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. *Cancer Res*. 2008 Oct 1;68(19):7788-94. doi: 10.1158/0008-5472.CAN-08-1053.
82. Kawakami A, Fisher DE. The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. *Lab Invest*. 2017 Jun;97(6):649-656. doi: 10.1038/labinvest.2017.9.
83. Jacquemin P, Lannoy VJ, O'Sullivan J, et al. The transcription factor onecut-2 controls the microphthalmia-associated transcription factor gene. *Biochem Biophys Res Commun*. 2001 Aug 3;285(5):1200-5.
84. Shoag J, Haq R, Zhang M, et al. PGC-1 coactivators regulate MITF and the tanning response. *Mol Cell*. 2013 Jan 10;49(1):145-57. doi: 10.1016/j.molcel.2012.10.027.
85. Riesenbergs S, Groetchen A, Siddaway R, et al. MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. *Nat Commun*. 2015 Nov 4;6:8755. doi: 10.1038/ncomms9755.

86. Ammoun S, Provenzano L, Zhou L, et al. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival. *Oncogene*. 2014 Jan 16;33(3):336-46. doi: 10.1038/onc.2012.587.
87. Fane ME, Chhabra Y, Hollingsworth DEJ, et al. NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF. *EBioMedicine*. 2017 Feb;16:63-75. doi: 10.1016/j.ebiom.2017.01.013.
88. Verfaillie A, Imrichova H, Atak ZK, et al. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. *Nat Commun*. 2015 Apr 9;6:6683. doi: 10.1038/ncomms7683.